Across TCGA pan-cancer cohorts, ANKRD39 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ANKRD39’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ANKRD39 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ANKRD39 is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where ANKRD39 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD39 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.500	<.001	7	view →
LUAD	All	II,III,IV	+0.241	<.001	7	view →
HNSC	Male	All	−0.385	.011	6	view →
PDAC	Male	All	−0.830	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ANKRD39 RNA expression & survival · all ANKRD39 data types